Prophylactic Enoxaparin in Critically Ill Trauma Patients: Evaluation of the Initial Dose

被引:1
|
作者
Agedal, Kaitlyn J. [1 ]
Feldman, Elizabeth A. [1 ]
Seabury, Robert W. [1 ]
Darko, William [1 ,2 ]
Probst, Luke A. [1 ,2 ]
Miller, Christopher D. [1 ,2 ]
Cwikla, Gregory M. [1 ]
机构
[1] Upstate Univ Hosp, Syracuse, NY 13210 USA
[2] Upstate Med Univ, Syracuse, NY USA
关键词
critical care; drug; medical use evaluation; monitoring drug therapy; anticoagulants;
D O I
10.1177/00185787211067374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Trauma patients are at increased risk of developing venous thromboembolism given alterations in the coagulation cascade. Chemoprophylaxis with standard dosing of enoxaparin 30 mg subcutaneously twice daily has evolved to incorporate the use of anti-factor Xa (AFXa) trough level monitoring given concerns for decreased enoxaparin bioavailability in this patient population. Current available evidence suggests low rates of goal AFXa trough level achievement with standard enoxaparin dosing. Our study aims to identify the incidence of critically ill trauma patients that did not achieve goal AFXa trough levels and attempts to identify predictors that may influence the lack of achievement of goal levels. Methods: This was a retrospective, cohort analysis performed at a single academic medical center. Adult patients 18 years or older admitted to the surgical intensive care unit secondary to trauma who were initiated on standard prophylactic enoxaparin and had at least 1 AFXa trough level representative of steady state were included. Patient demographics and clinical data were collected, and descriptive statistics were utilized. All statistical tests were 2-tailed and a P < .05 was considered significant. Variables with a P < .10 on univariable analysis were included in a multivariable logistic regression analysis. Results: A majority of our patient population did not achieve goal AFXa trough levels while receiving standard doses of prophylactic enoxaparin (82.4% [108/131]). Sub-target AFXa levels were associated with higher creatinine clearance values. Positive predictors of obtaining target AFXa levels included automobile versus pedestrian mechanism of injury and requiring an enoxaparin dose escalation to at least 40 mg twice daily. Conclusions: Our study found low rates of achievement of goal AFXa trough levels in critically ill trauma patients receiving standard prophylactic enoxaparin dosing. Certain variables were identified as negative and positive predictors for achievement of goal AFXa trough levels, although the biologic plausibility of these predictors is questionable and requires further investigation.
引用
收藏
页码:540 / 545
页数:6
相关论文
共 50 条
  • [1] Optimal dose of enoxaparin in critically ill trauma and surgical patients
    Rutherford, EJ
    Schooler, WG
    Sredzienski, E
    Abrams, JE
    Skeete, DA
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2005, 58 (06): : 1167 - 1170
  • [2] Prophylactic enoxaparin in critically ill patients with severe renal insufficiency
    Castellucci, L. A.
    Shaw, J.
    Acres, S.
    Porteous, R.
    Gomes, B.
    Watpool, I
    Edwards, C.
    Giulivi, A.
    Carrier, M.
    Patel, R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 213 - 214
  • [3] Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved
    Nunez, Jade M.
    Becher, Robert D.
    Rebo, Gerald J.
    Farrah, Jason P.
    Stirparo, Joseph J.
    Lauer, Cynthia
    Kilgo, Patrick
    Miller, Preston R.
    [J]. AMERICAN SURGEON, 2015, 81 (06) : 605 - 609
  • [4] Prophylactic anticoagulation with low dose enoxaparin -: Is the subcutaneous route appropriate in the critically ill?
    Priglinger, U
    Delle Karth, G
    Geppert, A
    Joukhadar, C
    Berger, R
    Hülsmann, M
    Pabinger, I
    Heinz, G
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (12) : A97 - A97
  • [5] Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
    U Priglinger
    G Delle Karth
    A Geppert
    C Joukhadar
    R Berger
    M Hülsmann
    I Pabinger
    G Heinz
    [J]. Critical Care, 6 (Suppl 1):
  • [6] Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin
    Danguy, Christine
    Biston, Patrick
    Carlier, Eric
    Defrance, Pierre
    Piagnerelli, Michael
    [J]. INTENSIVE CARE MEDICINE, 2012, 38 (11) : 1904 - 1905
  • [7] Thrombelastography Versus AntiFactor Xa Levels in the Assessment of Prophylactic-Dose Enoxaparin in Critically Ill Patients
    Van, Philbert Y.
    Cho, S. David
    Underwood, Samantha J.
    Morris, Melanie S.
    Watters, Jennifer M.
    Schreiber, Martin A.
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2009, 66 (06): : 1509 - 1517
  • [8] Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin
    Christine Danguy
    Patrick Biston
    Eric Carlier
    Pierre Defrance
    Michael Piagnerelli
    [J]. Intensive Care Medicine, 2012, 38 : 1904 - 1905
  • [9] Prophylactic anticoagulation with enoxaparin:: Is the subcutaneous route appropriate in the critically ill?
    Priglinger, U
    Delle Karth, G
    Geppert, A
    Joukhadar, C
    Graf, S
    Berger, R
    Hülsmann, M
    Spitzauer, S
    Pabinger, I
    Heinz, G
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (05) : 1405 - 1409
  • [10] Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients
    Helviz, Yigal
    Dzigivker, Ilia
    Raveh-Brawer, David
    Hersch, Moshe
    Zevin, Shoshana
    Einav, Sharon
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (02): : 108 - 113